자동 유방 초음파 영상 진단 시스템 시장 : 시장 예측(2026-2032년)

The Automatic Breast Ultrasound Imaging System Market is projected to grow by USD 4.71 billion at a CAGR of 10.71% by 2032.

Automatic Breast Ultrasound Imaging Systems: Executive Overview

Automatic breast ultrasound imaging systems use mechanized transducers and software-guided image acquisition to produce standardized breast examinations. Their relevance is strongest where clinicians need supplemental evaluation for dense breast tissue, repeatable scanning, and improved workflow consistency alongside mammography and other established diagnostic methods. Adoption depends on clinical evidence, regulatory clearance, reimbursement, equipment integration, operator training, and the ability to fit imaging pathways without creating unnecessary follow-up procedures.

Workflow Standardization Is Reshaping Breast Imaging

The landscape is shifting from highly operator-dependent ultrasound examinations toward more reproducible acquisition, structured interpretation, and integrated review. Automated scanning can support consistent coverage, image archiving, and retrospective assessment, while improvements in probes, three-dimensional reconstruction, and workstation ergonomics are addressing earlier usability constraints. These systems are not a replacement for diagnostic judgment: abnormal findings may still require targeted ultrasound, biopsy, magnetic resonance imaging, or other clinical evaluation. Adoption therefore favors solutions that demonstrate practical workflow value, interoperability, and clear patient-selection criteria.

Artificial Intelligence Is Extending Detection and Workflow Support

Artificial intelligence is increasingly relevant to automatic breast ultrasound through lesion detection, image quality assessment, segmentation, triage, and decision support. Its cumulative impact will depend on representative training data, transparent performance validation, calibration across scanners and populations, and effective integration into radiology workflows. AI should be positioned as an aid to qualified professionals rather than an autonomous diagnostic substitute. Governance priorities include human oversight, cybersecurity, auditability, bias monitoring, and clear communication of uncertainty when algorithms encounter uncommon anatomy or technically limited studies.

Regional Conditions Create Distinct Adoption Pathways

North America is shaped by dense-breast screening discussions, established imaging infrastructure, reimbursement variation, and strong requirements for clinical and regulatory evidence. Europe combines advanced breast-imaging capability with country-level procurement and reimbursement differences, while the European Union places added emphasis on medical-device compliance, data protection, and cross-border digital governance. Asia-Pacific spans highly mature systems in Japan, South Korea, and Australia alongside rapidly expanding access needs in China and India. Latin America is influenced by uneven equipment distribution, public-sector capacity, and specialist availability. The Middle East, particularly the GCC, often combines well-resourced urban providers with national screening initiatives, whereas Africa faces greater constraints in access, maintenance, workforce capacity, and referral continuity.

International Groups Reveal Different Policy and Procurement Priorities

ASEAN markets differ materially in screening infrastructure, regulatory maturity, and public-private delivery models, making adaptable implementation important. BRICS economies combine major urban centers with substantial internal variation in access, reimbursement, and diagnostic workforce capacity. The European Union emphasizes harmonized standards while retaining national purchasing and care pathways. G7 countries generally have mature imaging ecosystems but continue to address workforce pressure, health-system efficiency, and equitable access. GCC members commonly prioritize centralized procurement, advanced hospital capability, and population screening development. NATO membership is not a healthcare market category, but its countries often share attention to resilient infrastructure, secure health data, and continuity of critical medical services.

Country-Level Priorities Span Screening, Access, and Integration

Australia and Canada are influenced by geographically dispersed populations and the need to connect centralized expertise with regional services. Brazil and Mexico must account for unequal access across public and private systems. China and India combine large potential patient populations with pronounced differences between metropolitan and rural care. Japan and South Korea have sophisticated imaging environments and strong interest in workflow efficiency and technical performance. France, Germany, Italy, Spain, and the United Kingdom operate within mature European systems where evidence, procurement, reimbursement, and workforce considerations shape deployment. Russia's adoption environment is affected by healthcare modernization, equipment availability, and regulatory conditions. In the United States, dense-breast notification practices, payer variation, regulatory requirements, and referral workflows are central considerations.

Prioritize Evidence, Interoperability, and Equitable Deployment

Industry leaders should define the clinical use case before selecting technology, distinguishing screening support from diagnostic assessment and specifying how positive findings will be managed. They should validate performance across breast densities, age groups, body types, and care settings; measure recall, biopsy, false-negative, examination-time, and workflow outcomes; and compare results with existing pathways. Interoperability with imaging archives, reporting systems, and cybersecurity controls should be treated as a purchase requirement. Implementation plans should include sonographer and radiologist training, maintenance coverage, quality assurance, patient communication, and referral capacity so that increased detection does not overwhelm downstream services.

Methodology: Evidence-Based Assessment of Clinical and Operating Context

This executive summary uses the defined market scope of automatic breast ultrasound imaging systems and organizes assessment around technology function, clinical workflow, regulation, reimbursement, infrastructure, workforce, and implementation conditions. Regional, group, and country narratives reflect structural healthcare characteristics rather than market estimates or forecasts. A rigorous full study would triangulate peer-reviewed clinical literature, regulatory documents, professional guidance, procurement records, health-system publications, and interviews with qualified stakeholders. Findings should be refreshed as evidence standards, reimbursement policies, AI governance, and screening recommendations change.

Conclusion: Adoption Depends on Demonstrable Clinical Utility

Automatic breast ultrasound imaging systems have the greatest strategic relevance when they improve examination consistency, support evaluation of dense breasts, and integrate into established diagnostic pathways without weakening clinical oversight. The opportunity is balanced by evidence requirements, variable infrastructure, downstream diagnostic capacity, and the need for responsible AI governance. Leaders that combine validated performance with interoperable technology, trained users, resilient service models, and equitable access will be better positioned to translate automation into dependable patient care.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. New Revenue Opportunities
• 3.4. Next-Generation Business Models
• 3.5. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Automatic Breast Ultrasound Imaging System Market, by Product Type

• 7.1. Introduction
• 7.2. Dedicated Automated Systems
  • 7.2.1. Portable Systems
  • 7.2.2. Stationary Systems
• 7.3. Integrated Systems
• 7.4. Optional Accessories
  • 7.4.1. Software Modules
  • 7.4.2. Transducer Probes

8. Automatic Breast Ultrasound Imaging System Market, by Technology

• 8.1. Introduction
• 8.2. Three Dimensional Ultrasound
• 8.3. Two Dimensional Ultrasound

9. Automatic Breast Ultrasound Imaging System Market, by Application

• 9.1. Introduction
• 9.2. Biopsy Guidance
  • 9.2.1. Needle Placement Guidance
  • 9.2.2. Tissue Sampling Assessment
• 9.3. Diagnostic
  • 9.3.1. Lesion Characterization
  • 9.3.2. Supplemental Diagnosis
• 9.4. Research
• 9.5. Screening
  • 9.5.1. Dense Breast Screening
  • 9.5.2. High Risk Screening
  • 9.5.3. Routine Screening

10. Automatic Breast Ultrasound Imaging System Market, by End User

• 10.1. Introduction
• 10.2. Ambulatory Care Centers
• 10.3. Diagnostic Imaging Centers
  • 10.3.1. Mobile Imaging Units
  • 10.3.2. Standalone Imaging Centers
• 10.4. Hospitals
  • 10.4.1. Cancer Centers
  • 10.4.2. General Hospitals
• 10.5. Specialty Clinics
  • 10.5.1. Breast Specialty Clinics
  • 10.5.2. Radiology Centers

11. Automatic Breast Ultrasound Imaging System Market, by Sales Channel

• 11.1. Introduction
• 11.2. Direct Sales
• 11.3. Distributors
• 11.4. Online Channels

12. Automatic Breast Ultrasound Imaging System Market, by Region

• 12.1. Introduction
• 12.2. Asia-Pacific
• 12.3. North America
• 12.4. Latin America
• 12.5. Europe
• 12.6. Middle East
• 12.7. Africa

13. Automatic Breast Ultrasound Imaging System Market, by Group

• 13.1. Introduction
• 13.2. ASEAN
• 13.3. GCC
• 13.4. European Union
• 13.5. BRICS
• 13.6. G7
• 13.7. NATO

14. Automatic Breast Ultrasound Imaging System Market, by Country

• 14.1. Introduction
• 14.2. United States
• 14.3. Canada
• 14.4. Mexico
• 14.5. Brazil
• 14.6. United Kingdom
• 14.7. Germany
• 14.8. France
• 14.9. Russia
• 14.10. Italy
• 14.11. Spain
• 14.12. China
• 14.13. India
• 14.14. Japan
• 14.15. Australia
• 14.16. South Korea

15. Competitive Landscape

• 15.1. Market Share Analysis, 2025
• 15.2. Market Concentration Analysis, 2025
  • 15.2.1. Concentration Ratio (CR)
  • 15.2.2. Herfindahl Hirschman Index (HHI)
• 15.3. Recent Developments & Impact Analysis, 2025
• 15.4. Product Portfolio Analysis, 2025
• 15.5. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. Alpinion Medical Systems Co., Ltd.
• 16.2. Canon Medical Systems Corporation
• 16.3. CapeRay Medical Ltd.
• 16.4. Esaote S.p.A.
• 16.5. Fujifilm Holdings Corporation
• 16.6. GE HealthCare Technologies Inc.
• 16.7. Hitachi, Ltd.
• 16.8. iSono Health, Inc.
• 16.9. Konica Minolta, Inc.
• 16.10. Koninklijke Philips N.V.
• 16.11. QT Imaging, Inc.
• 16.12. Samsung Medison Co., Ltd.
• 16.13. Siemens Healthineers AG

17. Key Experts